Document Detail

Development of vitiligo during melanoma treatment with a novel survivin inhibitor: a case report and review of the literature.
MedLine Citation:
PMID:  19335434     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The development of vitiligo has been associated with an improved clinical response in melanoma patients. METHODS: We report a case of vitiligo associated with a novel antisurvivin drug and review the literature to determine the pathogenesis of vitiligo occurring during melanoma treatment. RESULTS: A 78-year-old man with stage IV malignant melanoma developed vitiligo after the first therapeutic cycle of a novel antisurvivin drug. Although his vitiligo remained static, his melanoma continued to progress and he died in 8 months. A review of the literature demonstrates a relationship between vitiligo development and improved clinical response in many melanoma cases treated with immunotherapy; however, the relationship may depend on the type of treatment. CONCLUSIONS: Understanding complex immune responses in vitiliginous skin and melanoma sites is important in order to interpret the development of vitiligo occurring during melanoma treatment.
Mayumi Fujita; Whitney A High; Shabnam Asgari; Karl D Lewis; Rene Gonzalez
Related Documents :
3457814 - Computed tomography of osteogenic sarcoma of nasal cavity and paranasal sinuses.
6484604 - Roentgenographic-pathologic correlation of diffuse sclerosis in ewing sarcoma of bone.
2433544 - Metastatic melanoma of the gallbladder: a case report and review of the literature.
2733164 - Thoracoscopy in the diagnosis of pleural effusions.
6661474 - Clinical differentiation of primary degenerative and multi-infarct dementia: a critical...
15624894 - Voriconazole-induced musical hallucinations.
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  International journal of dermatology     Volume:  48     ISSN:  1365-4632     ISO Abbreviation:  Int. J. Dermatol.     Publication Date:  2009 Apr 
Date Detail:
Created Date:  2009-04-01     Completed Date:  2009-07-13     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0243704     Medline TA:  Int J Dermatol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  426-30     Citation Subset:  IM    
Department of Dermatology and Division of Medical Oncology, University of Colorado at Denver and Health Sciences Center, Aurora, Colorado 80010-7163, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antineoplastic Agents / administration & dosage,  adverse effects*
Imidazoles / administration & dosage,  adverse effects*
Melanoma / drug therapy*
Microtubule-Associated Proteins / antagonists & inhibitors*
Naphthoquinones / administration & dosage,  adverse effects*
Skin Neoplasms / drug therapy*
Vitiligo / chemically induced*,  pathology
Reg. No./Substance:
0/Antineoplastic Agents; 0/BIRC5 protein, human; 0/Imidazoles; 0/Microtubule-Associated Proteins; 0/Naphthoquinones; 0/YM 155

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Are we aware of all complications following body piercing procedures?
Next Document:  Effects of tacrolimus ointment on the expression of substance P, nerve growth factor, and neurotroph...